Adaptive Biotechnologies Corporation
General ticker "ADPT" information:
- Sector: Health Care
- Industry: Life Sciences Tools & Services
- Capitalization: $1.5B (TTM average)
Adaptive Biotechnologies Corporation follows the US Stock Market performance with the rate: 60.8%.
Estimated limits based on current volatility of 5.0%: low 17.15$, high 18.94$
Factors to consider:
- Total employees count: 619 (-12.7%) as of 2024
- Top business risk factors: Significant losses, Market acceptance, Strategic risks and growth management, Product liability, Regulatory and compliance
- Current price 82.7% above estimated high
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [4.19$, 9.56$]
- 2025-12-31 to 2026-12-31 estimated range: [3.56$, 8.31$]
Financial Metrics affecting the ADPT estimates:
- Negative: with PPE of -6.0 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -10.42 <= 0.33
- Positive: 18.93 < Shareholder equity ratio, % of 37.58 <= 41.86
- Positive: Investing cash flow per share per price, % of 8.51 > -0.66
- Negative: negative Net income
- Negative: negative Industry operating cash flow (median)
- Positive: Inventory ratio change, % of -4.17 <= -0.75
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term ADPT quotes
Long-term ADPT plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $185.31MM | $170.28MM | $178.96MM |
| Operating Expenses | $385.49MM | $397.31MM | $341.51MM |
| Operating Income | $-200.19MM | $-227.03MM | $-162.55MM |
| Non-Operating Income | $-0.18MM | $1.73MM | $2.95MM |
| Interest Expense | $4.24MM | $13.80MM | $11.58MM |
| R&D Expense | $141.76MM | $122.12MM | $102.95MM |
| Income(Loss) | $-200.37MM | $-225.30MM | $-159.59MM |
| Profit(Loss)* | $-200.19MM | $-225.25MM | $-159.49MM |
| Stockholders Equity | $464.17MM | $308.40MM | $202.71MM |
| Inventory | $14.45MM | $14.45MM | $8.44MM |
| Assets | $856.62MM | $661.13MM | $539.38MM |
| Operating Cash Flow | $-183.94MM | $-156.32MM | $-95.21MM |
| Capital expenditure | $16.35MM | $10.70MM | $3.66MM |
| Investing Cash Flow | $2.90MM | $129.65MM | $77.79MM |
| Financing Cash Flow | $132.26MM | $2.25MM | $0.24MM |
| Earnings Per Share** | $-1.40 | $-1.56 | $-1.08 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.